228 related articles for article (PubMed ID: 9858413)
1. Determination of skin concentrations of enrofloxacin in dogs with pyoderma.
DeManuelle TC; Ihrke PJ; Brandt CM; Kass PH; Vulliet PR
Am J Vet Res; 1998 Dec; 59(12):1599-604. PubMed ID: 9858413
[TBL] [Abstract][Full Text] [Related]
2. Cortical bone concentrations of enrofloxacin in dogs.
Duval JM; Budsberg SC
Am J Vet Res; 1995 Feb; 56(2):188-92. PubMed ID: 7717584
[TBL] [Abstract][Full Text] [Related]
3. Determination of plasma and skin concentrations of orbifloxacin in dogs with clinically normal skin and dogs with pyoderma.
Kay-Mugford PA; Weingarten AJ; Ngoh M; Zolynas R; White A; Katz T; Simmons R; Varma KJ
Vet Ther; 2002; 3(4):402-8. PubMed ID: 12584677
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetic evaluation of enrofloxacin administered orally to healthy dogs.
Walker RD; Stein GE; Hauptman JG; MacDonald KH
Am J Vet Res; 1992 Dec; 53(12):2315-9. PubMed ID: 1335707
[TBL] [Abstract][Full Text] [Related]
5. Antimicrobial activity of enrofloxacin against Staphylococcus intermedius strains isolated from canine pyodermas.
Ganière JP; Médaille C; Limet A; Ruvoen N; André-Fontaine G
Vet Dermatol; 2001 Jun; 12(3):171-5. PubMed ID: 11420933
[TBL] [Abstract][Full Text] [Related]
6. Plasma concentrations of enrofloxacin and its active metabolite ciprofloxacin in dogs following single oral administration of enrofloxacin at 7.5, 10, or 20 mg/kg.
Boothe DM; Boeckh A; Boothe HW; Wilkie S; Jones S
Vet Ther; 2002; 3(4):409-19. PubMed ID: 12584678
[TBL] [Abstract][Full Text] [Related]
7. Treatment of canine pyoderma with ibafloxacin and marbofloxacin--fluoroquinolones with different pharmacokinetic profiles.
Horspool LJ; van Laar P; van den Bos R; Mawhinney I
J Vet Pharmacol Ther; 2004 Jun; 27(3):147-53. PubMed ID: 15189300
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics of enrofloxacin in adult horses and concentration of the drug in serum, body fluids, and endometrial tissues after repeated intragastrically administered doses.
Giguère S; Sweeney RW; Bélanger M
Am J Vet Res; 1996 Jul; 57(7):1025-30. PubMed ID: 8807015
[TBL] [Abstract][Full Text] [Related]
9. Enrofloxacin concentrations in dogs with normal prostate and dogs with chronic bacterial prostatitis.
Dorfman M; Barsanti J; Budsberg SC
Am J Vet Res; 1995 Mar; 56(3):386-90. PubMed ID: 7771709
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics of enrofloxacin and its metabolite ciprofloxacin after intravenous and intramuscular administrations in sheep.
Mengozzi G; Intorre L; Bertini S; Soldani G
Am J Vet Res; 1996 Jul; 57(7):1040-3. PubMed ID: 8807018
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetic variables and tissue residues of enrofloxacin and ciprofloxacin in healthy pigs.
Anadón A; Martínez-Larrañaga MR; Díaz MJ; Fernández-Cruz ML; Martínez MA; Frejo MT; Martínez M; Iturbe J; Tafur M
Am J Vet Res; 1999 Nov; 60(11):1377-82. PubMed ID: 10566812
[TBL] [Abstract][Full Text] [Related]
12. Use of enrofloxacin.
Dick GC
Vet Rec; 1993 Jun; 132(24):616. PubMed ID: 8393228
[No Abstract] [Full Text] [Related]
13. Pharmacokinetics of enrofloxacin in clinically normal dogs and mice and drug pharmacodynamics in neutropenic mice with Escherichia coli and staphylococcal infections.
Meinen JB; McClure JT; Rosin E
Am J Vet Res; 1995 Sep; 56(9):1219-24. PubMed ID: 7486402
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics and residues of enrofloxacin in chickens.
Anadón A; Martínez-Larrañaga MR; Díaz MJ; Bringas P; Martínez MA; Fernàndez-Cruz ML; Fernández MC; Fernández R
Am J Vet Res; 1995 Apr; 56(4):501-6. PubMed ID: 7785830
[TBL] [Abstract][Full Text] [Related]
15. Development of resistant bacteria isolated from dogs with otitis externa or urinary tract infections after exposure to enrofloxacin in vitro.
Brothers AM; Gibbs PS; Wooley RE
Vet Ther; 2002; 3(4):493-500. PubMed ID: 12584687
[TBL] [Abstract][Full Text] [Related]
16. Effect of enrofloxacin on digoxin clearance and steady-state serum concentrations in dogs.
Novotny MJ; Shaw DH
Can J Vet Res; 1991 Apr; 55(2):113-6. PubMed ID: 1884291
[TBL] [Abstract][Full Text] [Related]
17. Susceptibility of canine and feline Escherichia coli and canine Staphylococcus intermedius isolates to fluoroquinolones.
Gottlieb S; Wigney DI; Martin PA; Norris JM; Malik R; Govendir M
Aust Vet J; 2008 Apr; 86(4):147-52. PubMed ID: 18363989
[TBL] [Abstract][Full Text] [Related]
18. Plasma and ear tissue concentrations of enrofloxacin and its metabolite ciprofloxacin in dogs with chronic end-stage otitis externa after intravenous administration of enrofloxacin.
Cole LK; Papich MG; Kwochka KW; Hillier A; Smeak DD; Lehman AM
Vet Dermatol; 2009 Feb; 20(1):51-9. PubMed ID: 19152587
[TBL] [Abstract][Full Text] [Related]
19. Serum concentrations and pharmacokinetics of enrofloxacin after intravenous and intragastric administration to mares.
Haines GR; Brown MP; Gronwall RR; Merritt KA
Can J Vet Res; 2000 Jul; 64(3):171-7. PubMed ID: 10935883
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of the clinical efficacy of marbofloxacin (Zeniquin) tablets for the treatment of canine pyoderma: an open clinical trial.
Paradis M; Abbey L; Baker B; Coyne M; Hannigan M; Joffe D; Pukay B; Trettien A; Waisglass S; Wellington J
Vet Dermatol; 2001 Jun; 12(3):163-9. PubMed ID: 11420932
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
